MedTrace Logo

MRI-guided Focal Laser Ablation Prostate Cancer

NCT05370482 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2022-10-26

No results posted yet for this study

Summary

Prostate cancer is the most frequent malignancy in the male population of developed countries and has a substantial socio-economic impact. Focal therapies, including focal laser ablation (FLA), are gaining ground as a novel strategy to treat organ-confined low- to intermediate risk PCa while preserving healthy tissue and reduce treatment-related morbidity associated with radical treatments.

This project has the goal to perform a feasibility study on magnetic resonance imaging (MRI)-guided focal laser ablation using the TRANBERG®\|Thermoguide Therapy System including TRANBERG®Thermoguide Workstation for MR thermometry developed by the company CLS AB.

Conditions

  • Prostate Neoplams, Magnetic Resonance Imaging, Laser Ablation

Interventions

DEVICE

Focal laser ablation

MRI-guided focal laser ablation for prostate cancer

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Jurgen Fütterer · Radboud University Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
76 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-11
Primary Completion
2023-10-11
Completion
2025-04-11

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05370482 on ClinicalTrials.gov